Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSStandard

YONDELIS

TRABECTEDIN

Standard Dose
1MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview YONDELIS is listed in Drugs@FDA under application 207953 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient TRABECTEDIN Form and strength POWDER;INTRAVENOUS - 1MG/VIAL Sponsor JANSSEN PRODS Submission history Latest submission status date: 2025-12-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview YONDELIS is listed in Drugs@FDA under application 207953 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient TRABECTEDIN Form and strength POWDER;INTRAVENOUS - 1MG/VIAL Sponsor JANSSEN PRODS Submission history Latest submission status date: 2025-12-23 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Prescription
  • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
YONDELIS (TRABECTEDIN) | Drug Monograph | MedicHelpline